F

or all the angst over the eye-popping prices for a pair of new gene therapies, an analysis finds the treatments are cost effective, at least for now.

The analysis examined two so-called CAR-T therapies — one is sold by Novartis for treating youngsters with advanced leukemia, and the other is sold by Gilead Sciences to treat a type of lymphoma in adults. They have a one-time cost of $475,000 and $373,000, respectively, but even at those prices, the drugs are considered more economical than standard chemotherapy treatment.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X